Harnessing lymphoma epigenetics to improve therapies
Open Access
- 18 November 2020
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 136 (21), 2386-2391
- https://doi.org/10.1182/blood.2020006908
Abstract
Affinity maturation and terminal differentiation of B cells via the germinal center reaction is a complex multistep process controlled by transcription factors that induce or suppress large dynamic transcriptional programs. This occurs via the recruitment of coactivator or corepressor complexes that epigenetically regulate gene expression by post-translationally modifying histones and/or remodeling chromatin structure. B-cell–intrinsic developmental programs both regulate and respond to interactions with other cells in the germinal center that provide survival and differentiation signals, such as T-follicular helper cells and follicular dendritic cells. Epigenetic and transcriptional programs that naturally occur during B-cell development are hijacked in B-cell lymphoma by genetic alterations that directly or indirectly change the function of transcription factors and/or chromatin-modifying genes. These in turn skew differentiation toward the tumor cell of origin and alter interactions between lymphoma B cells and other cells within the microenvironment. Understanding the mechanisms by which genetic alterations perturb epigenetic and transcriptional programs regulating B-cell development and immune interactions may identify opportunities to target these programs using epigenetic-modifying agents. Here, we discuss recently published studies centered on follicular lymphoma and diffuse large B-cell lymphoma within the context of prior knowledge, and we highlight how these insights have informed potential avenues for rational therapeutic interventions.This publication has 39 references indexed in Scilit:
- Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentationProceedings of the National Academy of Sciences of the United States of America, 2015
- Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitorsProceedings of the National Academy of Sciences of the United States of America, 2014
- Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell LymphomaCancer Cell, 2013
- EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid TransformationCancer Cell, 2013
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- Inactivating mutations of acetyltransferase genes in B-cell lymphomaNature, 2011
- Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylationBlood, 2011
- EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesisBlood, 2010
- Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomasProceedings of the National Academy of Sciences of the United States of America, 2010
- Distinct expression patterns of polycomb oncoproteins and their binding partners during the germinal center reactionEuropean Journal of Immunology, 2004